Effect of advanced glycation end-products in a wide range of medical problems including COVID-19

Adv Med Sci. 2024 Mar;69(1):36-50. doi: 10.1016/j.advms.2024.01.003. Epub 2024 Feb 8.

Abstract

Glycation is a physiological process that determines the aging of the organism, while in states of metabolic disorders it is significantly intensified. High concentrations of compounds such as reducing sugars or reactive aldehydes derived from lipid oxidation, occurring for example in diabetes, atherosclerosis, dyslipidemia, obesity or metabolic syndrome, lead to increased glycation of proteins, lipids and nucleic acids. The level of advanced glycation end-products (AGEs) in the body depends on rapidity of their production and the rate of their removal by the urinary system. AGEs, accumulated in the extracellular matrix of the blood vessels and other organs, cause irreversible changes in the biochemical and biomechanical properties of tissues. As a consequence, micro- and macroangiopathies appear in the system, and may contribute to the organ failure, like kidneys and heart. Elevated levels of AGEs also increase the risk of Alzheimer's disease and various cancers. In this paper, we propose a new classification due to modified amino acid residues: arginyl-AGEs, monolysyl-AGEs and lysyl-arginyl-AGEs and dilysyl-AGEs. Furthermore, we describe in detail the effect of AGEs on the pathogenesis of metabolic and old age diseases, such as diabetic complications, atherosclerosis and neurodegenerative diseases. We summarize the currently available data on the diagnostic value of AGEs and present the AGEs as a therapeutic goal in a wide range of medical problems, including SARS-CoV-2 infection and so-called long COVID.

Keywords: Advanced glycation end-products; Alzheimer's disease; COVID-19; Diabetes; Metabolic diseases.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / metabolism
  • COVID-19* / metabolism
  • COVID-19* / virology
  • Diabetes Complications / metabolism
  • Glycation End Products, Advanced* / metabolism
  • Humans
  • Neurodegenerative Diseases / metabolism
  • SARS-CoV-2* / isolation & purification
  • SARS-CoV-2* / metabolism

Substances

  • Glycation End Products, Advanced